Karolinska Institutet

27 trials 9 recruiting Academic / non-commercial

Filter these 27 trials by condition, phase, country and more.

Open in Search →

27 Registered trials

9 Recruiting

6 Completed trials

7 Countries active

58 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase IV

Phase III: 6 Phase II/III: 1 Phase II: 9 Phase I/II: 3 Phase III/IV: 1 Phase IV: 5 Phase I: 2

Oversight events:

5 temporary halts across 3 trials

View oversight register →

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Rheumatoid arthritis 1 Acute myocardial infarction 1 Congo-Crimean haemorrhagic fever 1 Prostate cancer metastatic 1 Chronic kidney disease 1 Breast cancer female 1 Ischaemic stroke 1 Rhinitis allergic 1 Allergic respiratory disease 1 Glioblastoma multiforme 1

Top IMPs

ACETYLSALICYLIC ACID 1 ALLOGENEIC FETAL MESENCHYMAL STEM CELLS 1 AMOXICILLIN 1 APIXABAN 1 CANIS FAMILIARIS (553) 1 CAPIVASERTIB 1 CERTOLIZUMAB PEGOL 1 CYCLOPHOSPHAMIDE 1 DAROLUTAMIDE 1 DESLORATADINE 1 DOCETAXEL 1 DOXORUBICIN HYDROCHLORIDE 1

All trials — page 2

27 total

A phase 3, randomised, double-blind, placebo-controlled, parallel-arm efficacy trial of Imatinib in acute ischaemic stroke Halted

2023-506178-11-00 Phase III 1 country IMATINIB MESILATE
A Phase I Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 against Crimean Congo Hemorrhagic Fever (CCHF-NP-1) Ended

2023-508556-18-00 Phase I 1 country
Alcohol Use and Behavior in Young Adults Ended

2022-501809-13-01 Phase II 1 country OXYTOCIN

Showing 25–27 of 27 trials

← All sponsors A–Z